U.S. Markets open in 8 hrs 17 mins
  • S&P Futures

    3,695.75
    +25.75 (+0.70%)
     
  • Dow Futures

    29,527.00
    +184.00 (+0.63%)
     
  • Nasdaq Futures

    11,400.50
    +84.25 (+0.74%)
     
  • Russell 2000 Futures

    1,679.10
    +16.60 (+1.00%)
     
  • Crude Oil

    77.43
    +0.72 (+0.94%)
     
  • Gold

    1,639.00
    +5.60 (+0.34%)
     
  • Silver

    18.47
    +0.06 (+0.35%)
     
  • EUR/USD

    0.9640
    +0.0029 (+0.2989%)
     
  • 10-Yr Bond

    3.8780
    0.0000 (0.00%)
     
  • Vix

    32.26
    +2.34 (+7.82%)
     
  • GBP/USD

    1.0770
    +0.0087 (+0.8099%)
     
  • USD/JPY

    144.5140
    -0.1660 (-0.1147%)
     
  • BTC-USD

    20,049.32
    +1,237.41 (+6.58%)
     
  • CMC Crypto 200

    458.80
    +25.70 (+5.93%)
     
  • FTSE 100

    7,020.95
    +2.35 (+0.03%)
     
  • Nikkei 225

    26,553.43
    +121.88 (+0.46%)
     

Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Catalyst Pharmaceuticals, Inc. (CPRX)

NEW YORK, NY / ACCESSWIRE / October 31, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Catalyst Pharmaceuticals, Inc. ("Catalyst" or the "Company") (CPRX). Investors who purchased Catalyst stock are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/cprx.

The investigation concerns whether Catalyst and certain of its officers and/or directors have violated federal securities laws.

On October 30, 2019, Catalyst issued a press release announcing "top-line results from CMS-001, a Phase 3 study evaluating amifampridine phosphate for the symptomatic treatment of genetically confirmed Congenital Myasthenic Syndromes (CMS) in adults and children aged 2 years and above." The press release advised investors that "[w]hile individual patient improvements were observed in some patient sub-groups, the trial did not meet its primary endpoint of subject global impression (SGI) or the secondary endpoint of muscle function measure (MFM) across all tested subtypes." On this news, Catalyst's stock price fell $0.74 per share, or 12.98%, to close at $4.96 per share on October 30, 2019.

If you are aware of any facts relating to this investigation, or purchased Catalyst shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/cprx. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC



View source version on accesswire.com:
https://www.accesswire.com/564839/Bronstein-Gewirtz-Grossman-LLC-Announces-Investigation-of-Catalyst-Pharmaceuticals-Inc-CPRX